R Squared’s Protalix BioTherapeutics PLX Stock Holding History

R Squared’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,632	Closed	-$26.3K	–	627
2025 Q4	$26.3K	Buy	+14,632	New	+$29.9K	0.01%	483

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

R Squared's PLX Position: Q1 2026 in Review

R Squared sold out of Protalix BioTherapeutics (PLX) in Q1 2026, closing a stake of 14,632 shares — an estimated $26.3K sold.

R Squared first reported a position in PLX in Q4 2025 and held it in 1 quarter. The position peaked at $26.3K in Q4 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

R Squared reported no remaining Protalix BioTherapeutics position as of Q1 2026 after selling out during the quarter.
R Squared sold 14,632 Protalix BioTherapeutics shares in Q1 2026, an estimated $26.3K.
R Squared first reported a position in Protalix BioTherapeutics in Q4 2025 and held it in 1 quarter.
R Squared's Protalix BioTherapeutics position peaked at $26.3K in Q4 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.